Key clinical point: Ixekizumab provided significantly greater improvement in joint and skin symptoms than did adalimumab in biologic-naive patients with active PsA.
Major finding: Treatment with ixekizumab achieved the primary endpoint of simultaneous improvement of 50% on American College of Rheumatology response criteria (ACR50) and 100% on the Psoriasis Area and Severity Index (PASI100) in 39% of patients, which was significantly higher than the rate of 26% with adalimumab.
Study details: The randomized, open-label SPIRIT-H2H study of 566 patients with active PsA.
Disclosures: The study was funded by Eli Lilly, which markets ixekizumab. Dr. Smolen reported research grants and/or honoraria from Eli Lilly and AbbVie, which markets adalimumab, as well as many other pharmaceutical companies.
Smolen J et al. Arthritis Rheumatol. 2019;71(suppl 10),.